Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODE™ Open Access Database

Jennifer N. Dines, Thomas J. Manley, Emily Svejnoha, Heidi M. Simmons, Ruth Taniguchi, Mark Klinger, Lance Baldo, Harlan Robins
doi: https://doi.org/10.1101/2020.08.17.20175158
Jennifer N. Dines
1Adaptive Biotechnologies, 1551 Eastlake Ave E, Ste 200, Seattle, WA 98102.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jdines{at}adaptivebiotech.com
Thomas J. Manley
1Adaptive Biotechnologies, 1551 Eastlake Ave E, Ste 200, Seattle, WA 98102.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Svejnoha
1Adaptive Biotechnologies, 1551 Eastlake Ave E, Ste 200, Seattle, WA 98102.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heidi M. Simmons
1Adaptive Biotechnologies, 1551 Eastlake Ave E, Ste 200, Seattle, WA 98102.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Taniguchi
1Adaptive Biotechnologies, 1551 Eastlake Ave E, Ste 200, Seattle, WA 98102.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Klinger
1Adaptive Biotechnologies, 1551 Eastlake Ave E, Ste 200, Seattle, WA 98102.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lance Baldo
1Adaptive Biotechnologies, 1551 Eastlake Ave E, Ste 200, Seattle, WA 98102.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harlan Robins
1Adaptive Biotechnologies, 1551 Eastlake Ave E, Ste 200, Seattle, WA 98102.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objectives The primary aim of this study is to increase our understanding of the adaptive immune response to the SARS-CoV-2 virus by assaying the peripheral immune repertoire for virus-associated T-cell receptors (TCRs). Secondary aims include identification and characterization of SARS-CoV-2–specific B-cell receptors (BCRs) and monoclonal antibodies (mAbs) generated by antibody-producing cells during and after acute infection.

Trial design ImmuneRACE is a prospective, single group, multi-cohort, exploratory study of unselected eligible participants exposed to, infected with, or recovering from SARS-CoV-2.

Participants Approximately 1000 individuals, aged 18 to 89 years and residing in 24 different geographic areas within the United States, will be enrolled, primarily using remote telemedicine technologies. Cohorts will be based on clinical history. Cohort 1 will include participants exposed to SARS-CoV-2 within 2 weeks of study entry. Cohort 2 participants will include those clinically diagnosed or with positive laboratory confirmation of active COVID-19 disease. Cohort 3 will comprise participants previously diagnosed with COVID-19 disease who have been deemed recovered based on two consecutive negative tests, clearance by a healthcare professional, or resolution of symptoms related to COVID-19. All participants must be able to communicate with the investigator and understand and comply with the requirements of the study. Protected populations and those who may not safely participate are not eligible for this study.

Intervention and comparator Blood samples and nasopharyngeal or oropharyngeal swabs will be collected from participants. Nasopharyngeal or oropharyngeal swabs will be collected by inserting a swab into the nose or throat of the participant. Samples will be shipped frozen or transported refrigerated or at room temperature to Adaptive Biotechnologies for processing, including, but not limited to, testing for coronavirus or other respiratory illnesses, DNA extraction, and TCR analysis. The immunoSEQ assay will be conducted using DNA extracted from blood samples. An electronic questionnaire will be administered to collect information pertaining to the participant’s medical history, symptoms, and diagnostic tests performed for COVID-19 disease. Participants will have the option to undergo additional blood draws and questionnaires over a 2-month period. In collaboration with Microsoft, we will use machine learning and artificial intelligence approaches to construct a classifier based on TCR repertoire data designed to accurately distinguish COVID-19–positive cases from unexposed controls (from the ImmuneCODE database of TCR sequences). A rigorous statistical analysis will be performed to validate the classifier.

Main outcomes The main outcomes of this study will include a comparison of disease-specific TCR signatures in patients and controls, identification of the immunodominant antigens that elicit a T-cell response to SARS-CoV-2, risk stratification based on an individual’s immune signature, and determination of immune signatures of patients exposed to SARS-CoV-2 that may allow earlier detection of infection compared to available tests.

Trial registration “ImmuneRACE – Immune Response Action to COVID-19 Events (Protocol ADAP-006, version 1.0; 5/8/2020) is registered with the US National Institutes of Health and can be accessed at ClinicalTrials.gov (NCT04494893).

Competing Interest Statement

JND, TJM, ES, HMS, RT, MK, LB and HR are employees of Adaptive Biotechnologies and have equity ownership. HR additionally has patents and royalties with Adaptive Biotechnologies.

Clinical Trial

NCT04494893

Funding Statement

The study is sponsored by Adaptive Biotechnologies, an immune-driven medicine company, in partnership with Microsoft, who are working together to decode the immune response to COVID-19 and will provide these data freely to researchers around the world. Additional study partners include LabCorp/Covance and Illumina.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ImmuneRACE Study has been approved by the Western Institutional Review Board (reference number 1-1281891-1) on March 17th, 2020. We certify that the trial has received appropriate ethical approval from WIRB as described. All participants will provide informed consent for sample collection and data use.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data and updates related to this clinical trial protocol will be curated on ClinicalTrials.gov where the trial has been registered as NCT04494893. Through a collaboration with Microsoft, TCR sequence data resulting from the primary aims of this study will be made publicly available through the open access database ImmuneCODE at www.immunecode.com.

https://www.immunecode.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 21, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODE™ Open Access Database
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODE™ Open Access Database
Jennifer N. Dines, Thomas J. Manley, Emily Svejnoha, Heidi M. Simmons, Ruth Taniguchi, Mark Klinger, Lance Baldo, Harlan Robins
medRxiv 2020.08.17.20175158; doi: https://doi.org/10.1101/2020.08.17.20175158
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODE™ Open Access Database
Jennifer N. Dines, Thomas J. Manley, Emily Svejnoha, Heidi M. Simmons, Ruth Taniguchi, Mark Klinger, Lance Baldo, Harlan Robins
medRxiv 2020.08.17.20175158; doi: https://doi.org/10.1101/2020.08.17.20175158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)